Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | FATE |
---|---|---|
09:32 ET | 3852 | 2.3 |
09:33 ET | 20046 | 2.29 |
09:35 ET | 2000 | 2.315 |
09:37 ET | 2600 | 2.32 |
09:39 ET | 4216 | 2.31 |
09:42 ET | 4815 | 2.325 |
09:44 ET | 600 | 2.315 |
09:46 ET | 2600 | 2.32 |
09:48 ET | 1000 | 2.345 |
09:50 ET | 413 | 2.34 |
09:51 ET | 6404 | 2.335 |
09:53 ET | 3400 | 2.3 |
09:55 ET | 3582 | 2.3 |
09:57 ET | 4391 | 2.305 |
10:00 ET | 4897 | 2.2908 |
10:02 ET | 5226 | 2.315 |
10:04 ET | 2107 | 2.34 |
10:06 ET | 863 | 2.335 |
10:08 ET | 5458 | 2.33 |
10:09 ET | 18176 | 2.38 |
10:11 ET | 6767 | 2.36 |
10:13 ET | 2254 | 2.365 |
10:15 ET | 1690 | 2.38 |
10:18 ET | 1556 | 2.39 |
10:20 ET | 100 | 2.4 |
10:22 ET | 31863 | 2.37 |
10:24 ET | 10100 | 2.375 |
10:26 ET | 7592 | 2.4 |
10:27 ET | 1635 | 2.395 |
10:29 ET | 1700 | 2.38 |
10:31 ET | 1863 | 2.39 |
10:33 ET | 1000 | 2.385 |
10:36 ET | 509 | 2.375 |
10:38 ET | 6801 | 2.365 |
10:40 ET | 1893 | 2.345 |
10:42 ET | 1690 | 2.34 |
10:44 ET | 3500 | 2.345 |
10:45 ET | 1200 | 2.345 |
10:47 ET | 2200 | 2.345 |
10:49 ET | 7345 | 2.34 |
10:51 ET | 1534 | 2.335 |
10:54 ET | 5793 | 2.355 |
10:56 ET | 200 | 2.36 |
10:58 ET | 500 | 2.355 |
11:00 ET | 100 | 2.355 |
11:02 ET | 2940 | 2.355 |
11:03 ET | 100 | 2.355 |
11:05 ET | 200 | 2.355 |
11:07 ET | 642 | 2.355 |
11:09 ET | 300 | 2.35 |
11:12 ET | 3493 | 2.345 |
11:14 ET | 3155 | 2.335 |
11:16 ET | 4628 | 2.335 |
11:18 ET | 4857 | 2.325 |
11:20 ET | 4551 | 2.33 |
11:21 ET | 1866 | 2.34 |
11:23 ET | 1100 | 2.34 |
11:25 ET | 200 | 2.335 |
11:27 ET | 10758 | 2.34 |
11:30 ET | 400 | 2.34 |
11:32 ET | 2022 | 2.355 |
11:34 ET | 9220 | 2.35 |
11:36 ET | 1883 | 2.335 |
11:38 ET | 5100 | 2.3301 |
11:39 ET | 1600 | 2.311 |
11:41 ET | 100 | 2.315 |
11:43 ET | 800 | 2.3 |
11:45 ET | 100 | 2.3 |
11:48 ET | 7489 | 2.29 |
11:50 ET | 5784 | 2.29 |
11:52 ET | 2474 | 2.285 |
11:54 ET | 4100 | 2.285 |
11:56 ET | 8673 | 2.29 |
11:59 ET | 310 | 2.295 |
12:01 ET | 9080 | 2.3 |
12:03 ET | 2953 | 2.32 |
12:10 ET | 3973 | 2.305 |
12:12 ET | 800 | 2.305 |
12:14 ET | 200 | 2.3012 |
12:15 ET | 9287 | 2.2894 |
12:17 ET | 3275 | 2.305 |
12:19 ET | 3800 | 2.3 |
12:21 ET | 200 | 2.3 |
12:24 ET | 200 | 2.29 |
12:26 ET | 100 | 2.29 |
12:28 ET | 5248 | 2.29 |
12:30 ET | 900 | 2.29 |
12:32 ET | 300 | 2.295 |
12:33 ET | 100 | 2.29 |
12:35 ET | 100 | 2.29 |
12:37 ET | 100 | 2.295 |
12:39 ET | 200 | 2.295 |
12:42 ET | 300 | 2.3 |
12:44 ET | 300 | 2.295 |
12:46 ET | 100 | 2.295 |
12:48 ET | 5164 | 2.285 |
12:50 ET | 3000 | 2.285 |
12:51 ET | 100 | 2.285 |
12:53 ET | 2500 | 2.285 |
12:55 ET | 3774 | 2.29 |
12:57 ET | 4813 | 2.28 |
01:00 ET | 1939 | 2.295 |
01:02 ET | 1040 | 2.295 |
01:04 ET | 1000 | 2.29 |
01:06 ET | 2176 | 2.31 |
01:08 ET | 2000 | 2.295 |
01:11 ET | 219 | 2.295 |
01:13 ET | 400 | 2.295 |
01:15 ET | 1970 | 2.295 |
01:18 ET | 1339 | 2.295 |
01:20 ET | 100 | 2.295 |
01:22 ET | 1500 | 2.3 |
01:24 ET | 500 | 2.305 |
01:26 ET | 400 | 2.3 |
01:27 ET | 700 | 2.31 |
01:29 ET | 2772 | 2.305 |
01:31 ET | 10596 | 2.293 |
01:33 ET | 3000 | 2.295 |
01:36 ET | 2189 | 2.3 |
01:38 ET | 500 | 2.29 |
01:40 ET | 756 | 2.29 |
01:42 ET | 16408 | 2.27 |
01:44 ET | 500 | 2.275 |
01:45 ET | 1739 | 2.275 |
01:47 ET | 9657 | 2.29 |
01:49 ET | 1100 | 2.29 |
01:54 ET | 6433 | 2.29 |
01:56 ET | 600 | 2.285 |
01:58 ET | 2367 | 2.285 |
02:02 ET | 300 | 2.28 |
02:03 ET | 4836 | 2.28 |
02:07 ET | 700 | 2.285 |
02:09 ET | 700 | 2.2808 |
02:12 ET | 1500 | 2.2847 |
02:16 ET | 171 | 2.28 |
02:18 ET | 100 | 2.285 |
02:20 ET | 1200 | 2.285 |
02:21 ET | 400 | 2.2812 |
02:23 ET | 1500 | 2.285 |
02:25 ET | 100 | 2.285 |
02:27 ET | 320 | 2.2811 |
02:30 ET | 1988 | 2.285 |
02:32 ET | 9595 | 2.2908 |
02:34 ET | 100 | 2.29 |
02:36 ET | 200 | 2.295 |
02:38 ET | 2300 | 2.295 |
02:39 ET | 500 | 2.295 |
02:41 ET | 100 | 2.3 |
02:43 ET | 500 | 2.295 |
02:45 ET | 1166 | 2.29 |
02:50 ET | 274 | 2.29 |
02:52 ET | 2228 | 2.295 |
02:54 ET | 7906 | 2.285 |
02:56 ET | 2657 | 2.285 |
02:57 ET | 399 | 2.285 |
02:59 ET | 5942 | 2.295 |
03:01 ET | 1700 | 2.2954 |
03:03 ET | 10683 | 2.28 |
03:06 ET | 299 | 2.28 |
03:08 ET | 1391 | 2.285 |
03:10 ET | 2251 | 2.285 |
03:12 ET | 665 | 2.285 |
03:14 ET | 12624 | 2.295 |
03:15 ET | 1977 | 2.29 |
03:17 ET | 200 | 2.3 |
03:19 ET | 400 | 2.295 |
03:21 ET | 11453 | 2.275 |
03:24 ET | 1201 | 2.275 |
03:26 ET | 8972 | 2.28 |
03:28 ET | 1465 | 2.275 |
03:30 ET | 800 | 2.275 |
03:32 ET | 1888 | 2.27 |
03:33 ET | 700 | 2.28 |
03:35 ET | 700 | 2.28 |
03:37 ET | 300 | 2.275 |
03:39 ET | 2136 | 2.2725 |
03:42 ET | 10412 | 2.265 |
03:44 ET | 7998 | 2.275 |
03:46 ET | 920 | 2.275 |
03:48 ET | 5727 | 2.27 |
03:50 ET | 2200 | 2.265 |
03:51 ET | 5683 | 2.2625 |
03:53 ET | 4594 | 2.26 |
03:55 ET | 6904 | 2.265 |
03:57 ET | 47540 | 2.245 |
04:00 ET | 28652 | 2.24 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Fate Therapeutics Inc | 220.9M | -1.3x | --- |
Heron Therapeutics Inc | 223.6M | -1.5x | --- |
Agenus Inc | 284.8M | -0.9x | --- |
2Seventy Bio Inc | 156.9M | -0.8x | --- |
Enanta Pharmaceuticals Inc | 194.8M | -1.5x | --- |
Rigel Pharmaceuticals Inc | 231.0M | -9.6x | --- |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.9M |
---|---|
Revenue (TTM) | $106.2M |
Shares Outstanding | 98.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.57 |
EPS | $-1.77 |
Book Value | $4.97 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.75% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.